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Mycoplasma pneumoniae, a self-replicating cell wall-deficient prokaryote, has a differentiated terminal or-
ganelle that is essential for cytadherence and gliding motility. P30, an important protein associated with the
terminal organelle, is required for the cytadherence and virulence of M. pneumoniae. P30 is a transmembrane
protein with an intracytoplasmic N terminus and an exposed C terminus. In the present study, we amplified
and sequenced the full-length p30 gene of Mycoplasma pneumoniae directly from 18 Indian asthmatic patients.
Sequence diversity was observed in the p30 genes from 16 clinical samples when the sequences were compared
with the sequence of strain M-129. We also successfully expressed a fragment of the p30 gene (P30B) that
includes the complete C-terminal proline-rich amino acid sequences in different Escherichia coli expression
systems. The maltose binding protein (MBP)-P30B fusion protein was recognized by M. pneumoniae-infected
patient sera in immunoblots, and the protein was immunogenic in mice. We further analyzed the reactivity of
the MBP-P30B fusion protein with patient sera in an enzyme-linked immunosorbent assay (ELISA) and
compared it with the reactivity obtained with a commercial kit (the Serion ELISA Classic kit). The sensitivity
and the specificity of the in-house ELISA were 78.57% and 89.47%, respectively. This study suggests that the
P30 protein can be used as an antigen along with other adhesin proteins for the immunodiagnosis of M.
pneumoniae infection.
Mycoplasma pneumoniae is a unique cell wall-deficient bac-
terium that causes chronic respiratory infections, including
bronchitis and primary atypical pneumonia, in humans. It ac-
counts for up to 30% of all community-acquired cases of pneu-
monia and is very common among primary school children and
their parents. M. pneumoniae is also responsible for other
respiratory tract infections, such as tracheobronchitis, bronchi-
olitis, and less severe upper respiratory tract infections in older
children and young adults (7, 14). A wide variety of extrapul-
monary manifestations, such as myocarditis and acute dissem-
inated encephalomyelitis, have also been associated with M.
pneumoniae infection (22). M. pneumoniae infection some-
times results in chronic pulmonary lung damage, and a growing
body of evidence supports a correlation of M. pneumoniae
infection with the exacerbation and recurrence of asthma
(5, 20).
M. pneumoniae has a complex cellular organization and pos-
sess a specialized tip organelle, a membrane-bound cell exten-
sion distinguished by an electron-dense core (2, 4). The well-
defined apical organelle mediates adherence to host cells
(cytadherence) and gliding motility (6). Analysis of an M. pneu-
moniae hemadsorption (HA)-negative mutant has resulted in
the identification of a number of proteins associated with
cytadherence, such as P1, P30, P116, and HMW 1 to 3 (3, 11,
16, 18). These proteins are localized on the apical organelle,
which is the leading end in the gliding motility. Among these
organelle-associated genes, P30 is required for cytadherence
and is associated with proper cell development (19). M. pneu-
moniae mutant M7, which exhibited a truncated P30 protein,
had lost the ability to adsorb to erythrocytes and to bind to
epithelial cells (17). P30 has also been shown to be associated
with gliding motility. M. pneumoniae HA mutant II-3, which
lacks the P30 protein, has been shown to be nonmotile, while
HA mutant II-7, which produces an altered P30 protein,
showed 50-fold less motility than that of the wild type (12, 13).
The p30 gene contains an open reading frame of 825 nucle-
otides that codes for a protein of 275 amino acids with a
calculated molecular mass of 29.743 kDa. The gene has only
one UGA codon (nucleotides 46 to 48), which codes for tryp-
tophan in the case of M. pneumoniae (8). P30 is a membrane-
bound protein that orients with the N terminus in the cyto-
plasm and the C terminus exposed on the cell surface. The
protein contains three types of repeat sequences at its carboxy
end. One stretch of Pro-Gly-Met-Ala-Pro-Arg occurs seven
times, whereas two stretches of Pro-Gly-Met-Pro-Pro-His and
Pro-Gly-Phe-Pro-Pro-Gln are repeated three times. On the
basis of the orientation of the protein, it is envisaged that the
C terminus of the P30 protein is exposed on the surface of M.
pneumoniae. It is likely to generate an immune response in M.
pneumoniae-infected patient sera and thus can be exploited for
the immunodetection of M. pneumoniae-infected human sera.
In the present study, we sequenced the full-length p30 gene
of M. pneumoniae directly from 18 clinical samples (throat
swabs) from asthma patients attending a pediatric asthma
clinic at the All India Institute of Medical Sciences (AIIMS),
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New Delhi, India. We also analyzed the reactivity of P30 with
M. pneumoniae-infected patient sera.
(This work is a part of the Ph.D. thesis work of Avanish
Kumar Varshney under the supervision of Rama Chaudhry at
the All India Institute of Medical Sciences, New Delhi, India.)
MATERIALS AND METHODS
Growth of M. pneumoniae. A standard strain of M. pneumoniae, FH-Liu, was
procured from the National Collection of Type Cultures (London, United King-
dom), reconstituted in PPLO broth, incubated aerobically at 37°C, and moni-
tored at regular intervals (24 h) for a color change (red-yellow). After 5 to 7 days,
the broth was subcultured on PPLO agar plates. The plates were incubated in 5%
CO2 at 37°C in candle jars with a sterile cotton ball soaked in water to maintain
the humidity and were examined microscopically at 5-day intervals at 10 mag-
nification, without opening the plates, for the presence of typical round granular
colonies. Suspected colonies were stained with Diene’s stain and checked by light
microscopy. Further confirmation of the isolates as M. pneumoniae was done by
the growth inhibition test.
Study group. A total of 150 patients between 5 and 15 years of age who had
previously been diagnosed with moderate or severe persistent asthma (1) and
who were attending the Pediatric Chest Clinic, AIIMS, during the period from
November 2004 to May 2006 were investigated. The study was approved by the
AIIMS Ethical Committee for Human and Animal Ethical Clearance, and the
consent of the patients’ parents was obtained before the children were included
in the study. Blood was collected intravenously and placed in a plain sterile tube.
The serum was separated by centrifugation at 3,000 rpm for 10 min and was
stored at 20°C until use. Throat swab specimens were collected from the study
group and were transported in PPLO broth medium for M. pneumoniae culture
and PCR.
PCR amplification of the p30 gene of M. pneumoniae. Throat swabs from the
infected patients were inoculated and incubated at 37°C in PPLO broth for 24 h,
and DNA extraction was carried out by the method previously described by
Stauffer et al. (21). Likewise, the standard strain was grown in PPLO broth for
72 h, and the DNA was extracted accordingly. The extracted DNA was stored at
20°C until use.
On the basis of the sequences available in the database, oligonucleotide primers
were designed to amplify the p30 gene from the M. pneumoniae genomic DNA (8).
Primers P30-PF (forward primer; 5-ATGAAGTTACCACCTCGAAGAAGC-3)
and P30-PR (reverse primer; 5-TTAGCGTTTTGGTGGAAAACCGGGTTG-3)
were used for the amplification of the p30 gene (Synthesized from Bio Basic,
Canada). PCR was performed in a 50-l reaction mixture containing 1 U of Taq
polymerase, 1 PCR buffer, 200 M deoxynucleoside triphosphates, 1.5 mM
MgCl2, 10 pmol of each primer, and 6 l of extracted DNA. The reaction conditions
were standardized at an initial denaturation of 94°C for 10 min, followed by 35 cycles
of 94°C for 30 s, 54°C for 45 s, and 72°C for 1 min 20 s. A final extension was done
at 72°C for 10 min. The PCR products were analyzed in a 1.2% agarose gel and
purified with a gel extraction kit (Qiagen, Hilden, Germany). The amplified product
was further cloned in the pGEMT-E vector. For the expression of the p30 gene and
its fragment in heterologous expression systems (pQE-30), the following primer set
was synthesized: forward primer P30-EF1 (5-CCATGGGACCATGAAGTTACC
ACCTCGAAGAAAGCTTAAACTGTTTTTATTAGCCTGGATG-3) and re-
verse primer P30-ER1 (5- GTCGACTGCAGCGTTTTGGTGGAAA ACCGGG
TTG-3). For the expression of the p30 gene (P30B) fragment in a pMAL-p2x vector
system, forward primer P30-EF2 (5-CCATGGGATCCGCAACCTTAATTTTGG
TACAGCAC-3) and reverse P30-ER1 primer were used (Fig. 1). Note that the
expression primer, P30-EF2, was designed to exclude the UGA codon region of the
p30 gene of M. pneumoniae.
Sequencing of p30 gene from clinical samples. The PCR products amplified
from 18 clinical samples were analyzed in a 1.2% agarose gel and purified with
a QIAquick PCR purification kit (Qiagen). The purified p30 gene was subse-
quently sequenced by automated DNA sequencing (ABI Prism 310 instrument;
Applied Biosystems, Foster City, CA). For each clinical sample, three indepen-
dent amplification and sequencing reactions were carried out.
The nucleotide sequences of the p30 gene amplified from the clinical samples
were compared with the p30 sequence of M. pneumoniae strain M129 (GenBank
accession no. M57245). Sequence analysis was performed with the Clustal W and
Gene Doc tools, and protein translation was done with the EditSeq tool of
DNAStar software (DNAStar Inc., Madison, WI) by using the Mycoplasma
coding table.
Cloning and expression of p30 gene and its fragment of M. pneumoniae. The
amplified and purified DNA fragment was ligated into the pGEMT-E vector
system (Promega, Madison, WI), according to the manufacturer’s protocol.
Briefly, a 10-l reaction mixture was set up with 10 ng vector DNA, 5.0 l of
ligation buffer (2), 1.0 l T4 DNA ligase (1 U), and 3 l of the PCR-amplified
product (insert DNA, 300 ng). The ligation reaction mixture was incubated at
4°C for 16 h and was transformed into chemically competent DH5 cells.
Colonies were selected by blue-white selection screening on Luria-Bertani
(LB) agar containing 100 g/ml of ampicillin, 20 mg of 5-bromo-4-chloro-3-
indolyl--D-galactopyranoside, and 200 mg/ml of isopropyl--D-thiogalacto-
pyranoside (IPTG) (Sigma). Individual white colonies from the plate were inoc-
ulated in 5 ml LB broth containing 100 g/ml of ampicillin and were allowed to
grow for 16 h at 37°C. Plasmids were extracted with a Qiagen mini-prep plasmid
extraction kit and digested with EcoRI to ensure the presence of the insert, and
sequencing was done to rule out any mutation in the sequence.
For expression, subcloning of the full-length P30 protein (P30A) and a frag-
ment of the p30 gene (P30B) was done in the pQE-30 vector and the pMAL-p2x
fusion vector, according to the manufacturer’s instructions, with some modifica-
tions (Fig. 1). Briefly, the pGEMT-E construct of the p30 gene was digested with
the BamHI and SalI restriction endonucleases, and the digestion mixture was
separated on a 1% agarose gel. The full-length P30 protein (825 bp) and the
fragment corresponding to the p30 gene (744 bp) were excised, and DNA was
eluted by using a gel extraction kit (Real Biotech Corporation, Germany). The
pQE-30 and pMAL-p2x vectors were also digested with the same restriction
endonucleases used to digest the insert. The digested vectors and insert were
ligated at 16°C overnight. The ligation mixtures were transformed into Esche-
richia coli M-15 cells (for the pQE-30 vector) and E. coli TB-1 cells (for the
pMAL-p2x vector). Transformants were selected on LB agar plates containing
100 g/ml ampicillin and 25 g/ml of kanamycin for the pQE-30 vector and 100
g/ml ampicillin for the pMAL-p2x fusion vector. The recombinants were
screened by restriction digestion and sequencing.
M-15 cells and TB-1 cells containing the recombinant plasmids were cultivated
in 5 ml of LB broth at 37°C with shaking until the optical density (OD) reached
0.4 to 0.6. Expression was induced by treatment with 1 mM IPTG for 5 h at 37°C.
Bacterial cells were collected by centrifugation and were further subjected to
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) to
analyze the expression of the recombinant proteins.
SDS-PAGE and Western blotting. The crude induced and uninduced lysates of
the samples were dissolved in 30 l of SDS sample buffer (62.5 mM Tris-HCl [pH
6.8], 10% glycerol, 2.3% [wt/vol] SDS, 5% [vol/vol] -mercaptoethanol, and
0.05% [wt/vol] bromophenol blue) and boiled for 10 min. The proteins were
resolved on a 10% SDS-polyacrylamide gel and stained with Coomassie brilliant
blue R-250. For immunoblotting, the protein was separated on a 10% SDS-
FIG. 1. Schematic diagram showing the primers used for amplification of the p30 gene and fragments for expression.
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polyacrylamide gel, and the fractionated proteins were transferred from the gel
onto the nitrocellulose membrane (Amersham) in a Transblot apparatus (Mini
Protein III; Bio-Rad). The membrane was blocked in blocking buffer (1 phos-
phate-buffered saline [PBS], 0.05% Tween 20, 5% milk) for 2 h. The blots were
washed and incubated with primary antibody for 1 h: anti-His (1:5,000 dilution;
Qiagen), anti-maltose binding protein (anti-MBP) antibody (1:5,000 dilution;
New England Biolabs), anti-M. pneumoniae antibody (1:5,000 dilution; National
Collection of Type Cultures), and patient sera (1:100 dilution). Later, the blots
were washed and incubated for 1 h with secondary antibody (1:2,000 dilutions of
anti-mouse, anti-rabbit, or anti-human antibody) conjugated to horseradish per-
oxidase. The bands were visualized with 3,3-diaminobenzidine tetrahydrochlo-
ride–H2O2 (Sigma-Aldrich).
Purification of recombinant proteins. After confirmation of the recombinant
protein by Western blotting, the rMPN30–pQE-30 recombinant protein was
purified by using a nickel-nitriloacetic acid column (Qiagen) and the rMPN30–
pMAL-p2x recombinant protein was purified on an amylose resin column (New
England Biolabs). For large-scale production, cells expressing the P30 protein
were grown in a 100-ml culture and were induced with 1 mM IPTG. The bacterial
cells were then harvested by centrifugation at 5,000  g, and the pellets were
resuspended in a buffer consisting of 10 mM Tris (pH 7.5) and 50 mM NaCl and
lysed by sonication with 1-min pulses at 1-min intervals 10 times. The soluble and
insoluble fractions were separated by centrifugation at 20,000  g and were
analyzed by SDS-PAGE.
The recombinant P30B protein (rMPN30–pQE-30) was purified under dena-
turing conditions by metal affinity chromatography with nickel-nitriloacetic acid
resin (Qiagen). Elutions were carried out with imidazole buffer (8 M urea, 20
mM Na2HPO4, 5 M NaCl, 500 mM imidazole). The protein was dialyzed in
dialysis buffer containing 50 mM Tris and 1 mM EDTA for 48 h, with buffer
changes every 12 h to remove the urea and imidazole. The purity of the recom-
binant protein was evaluated by SDS-PAGE.
Another recombinant P30B protein (rMPN30–pMAL-p2x) was purified under
soluble conditions by using affinity chromatography with amylose resin (New
England Biolabs), according to the manufacturer’s protocol, with some modifi-
cations. Elutions were carried out with maltose buffer (10 mM maltose, 10 mM
Tris, and 500 mM NaCl). Fractions containing the purified recombinant protein
were pooled and dialyzed against PBS. The column eluent containing rMPN30–
pMAL-p2x was concentrated by centrifugation with Centricon-30 concentrators
(Amicon Inc., Beverly, MA). The concentrated rMPN30–pMAL-p2x protein was
run on an SDS-polyacrylamide gel stained with Coomassie blue R-250, and the
desired protein band was excised from the gel with a sterile razor blade and
electroeluted by using a GeBAflex-tube kit (Gene Bio-Application Ltd., Israel).
The protein concentration was determined by the Bradford method.
Immunization of mice. All animal experiments were carried out with the
approval of the Animal Ethics Committee, in accordance with the rules and
regulations set forth by the AIIMS Animal Ethics Committee. Immunization was
carried out with 6- to 8-week-old female Swiss albino mice, which were main-
tained in the animal facility of AIIMS. The Swiss albino mice were administered
40 g MBP-P30B fusion protein emulsified in 200 l of complete Freund’s
adjuvant (CFA; Sigma) intraperitoneally. Subsequent booster injections were
given on the 21st, 35th, and 49th days by injecting 40 g of the MBP-P30B fusion
protein emulsified in 200 l of incomplete Freund’s adjuvant (IFA; Sigma)
intraperitoneally. Control mice were injected with CFA and IFA in PBS accord-
ing to the immunization schedule. Blood samples were obtained from each
mouse by bleeding of the tail vein at 14, 21, 35, 42, and 56 days. The serum was
separated by centrifugation of clotted blood and was stored at 20°C for further
analysis. The titers of antibodies against the recombinant protein were deter-
mined by enzyme-linked immunosorbent assay (ELISA).
Comparative ELISA with purified P30 fusion protein and commercial IgM
assay. Serum was separated by centrifugation of clotted blood from patients at
3,000 rpm for 10 min and was subjected to an immunoglobulin M (IgM) ELISA
(ELISA Classic; Serion, Germany) for the detection of anti-M. pneumoniae
antibodies. A total of 47 patient serum samples (28 positive and 19 negative
patient serum samples tested for the investigation of M. pneumoniae with the
commercial Serion ELISA Classic kit) were included in this study. Due to
inadequate sample volumes, the remaining 103 specimens could not be tested for
P30 antibodies. MBP and the alpha subunit of the beta-galactosidase protein
were used as negative controls in the ELISA experiments.
The antibody response to the recombinant fusion protein (rMPN30–pMAL-
p2x) was evaluated by an ELISA for IgM antibodies. The experiment was done
in duplicate. A total of 100 l of coating buffer (0.1 M bicarbonate, pH 9.3)
containing 100 ng of the P30 protein was added to 96-well microtiter plates, and
the plates were incubated overnight at 4°C. The plates were then washed with
PBS–0.05% Tween 20 (PBS-T) and blocked with 5% bovine serum albumin in
PBS (pH 7.4) for 2 h. The plates were washed twice with PBS-T and once with
PBS and were then incubated with the individual patient sera (1:100 dilution) at
37°C for 1 h. The wells were washed and then incubated with horseradish
peroxidase-conjugated anti-human IgM (Sigma) diluted 1:3,000 in PBS-T for 1 h
at 37°C. The plates were washed three times with PBS-T, and the color was
developed by adding 100 l of 3,3,5,5-tetramethylbenzidine–H2O2 substrate
(Banglore Genei, India) and incubation in the dark for 20 min. The reaction was
stopped by adding 100 l of 2 N H2SO4, and the absorbance was read at a
wavelength of 450 nm with an ELISA reader (Bio-Tek Microplate reader). The
sample was considered positive if the OD at 450 nm was 0.5.
Statistical analysis. Data management was done on an Excel spreadsheet. All
entries were checked for any keyboard errors. The sensitivity and the specificity
of the in-house P30 ELISA were calculated by using Epi-6 software.
Nucleotide sequence accession number. The sequence presented in this study
has been submitted to the NCBI GenBank database and can be found under
accession no. EF 614306.
RESULTS
PCR amplification and analysis of p30 gene from Indian
clinical samples. The full-length p30 gene (825 bp) was ampli-
fied by PCR from genomic DNA isolated from 18 clinical
samples that were PCR positive for the p1 gene (Fig. 1). Of the
18 M. pneumoniae-infected clinical samples, 2 samples showed
sequences similar to that of the p30 gene of strain M-129.
Sixteen clinical samples showed four base substitutions at po-
sitions 239, 323, 583, and 696 that resulted into three amino
acid changes at positions 80, 108, and 195 (valine-glycine,
leucine-serine, and proline-serine, respectively). The last nu-
cleotide substitution was a silent mutation that did not result in
a change at amino acid position 232 (glycine-glycine). The
sequences of 16 samples showed similarity to the sequence of
the p30 gene of strain FH-Liu, which was also sequenced in the
present study (Fig. 2). Three independent sequencing reac-
tions were carried out for each clinical sample.
Expression and purification of recombinant P30 protein
fragment. The full-length p30 gene, i.e., P30A (825 bp), and a
smaller fragment of the p30 gene, i.e., P30B (744 bp), were
amplified by PCR and cloned into an E. coli expression vector,
pQE-30 (Fig. 1). No significant expression was observed after
IPTG induction for the full-length P30 protein. Nevertheless, a
moderate level of expression was seen in the case of the P30B
(rMPN30–pQE-30) protein, as indicated by Western blot anal-
ysis with anti-penta-His antibody (Fig. 3B). The apparent mo-
lecular mass of the protein was approximately 40 kDa. How-
ever, upon fractionation, the protein was found in the pellet
fraction of E. coli. The protein was subsequently purified on a
nickel-nitriloacetic acid affinity column under denaturing con-
ditions (Fig. 3A), and the denatured protein was recognized by
anti-M. pneumoniae antibody (Fig. 3C). Our attempts to purify
and refold the protein under nondenaturing conditions repeat-
edly failed.
Next, we expressed the P30B protein as an MBP fusion
protein (rMPN30–pMAL-p2x) in E. coli by cloning the gene
fragment in the pMAL-p2x vector. The fusion protein was
expressed as a soluble protein of approximately 87 kDa, as
detected with anti-MBP antibody (Fig. 4A). The rMPN30–
pMAL-p2x fusion protein was purified on an amylose column,
and the protein was purified up to a level of 	80% (Fig. 4B).
To further purify the protein to homogeneity, the rMPN30–
pMAL-p2x fusion protein was run on a 10% SDS- polyacryl-
amide gel, and the gel was stained with Coomassie blue R-250.
The major band pertaining to the MBP-P30 fusion protein was
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cut and electroeluted from the gel. Figure 4 shows the Coo-
massie blue-stained SDS-polyacrylamide gels of the eluted P30
protein. The purified protein was recognized well by anti-M.
pneumoniae antibodies (Fig. 4D).
Immunoblot analysis of recombinant P30 protein with M.
pneumoniae-infected patient sera. To know whether the P30B
(rMPN30–pMAL-p2x) protein induced an immunological re-
sponse, we analyzed the reactivity of the rMPN30–pMAL-p2x
fusion protein with sera from 28 patients (18 positive and 10
negative sera). Immunoblot analyses of the eight representa-
tive patient serum samples are shown in Fig. 5. M. pneumoniae-
infected patient sera recognized the protein very well on West-
ern blots, while sera from uninfected patients did not show
reactivity with the recombinant protein. These results indicate
that M. pneumoniae-infected patients have circulating anti-P30
antibodies, thereby suggesting that the P30 protein is immu-
nogenic.
Immunogenicity of rMPN30–pMAL-p2x fusion protein. To
know whether the P30 protein generates an immune response
in mice, the recombinant P30 protein was formulated in CFA
and was injected into mice. The immune response against the
MBP-P30B protein is shown in Fig. 6. High antibody responses
were observed with the CFA or the IFA formulation. The time
course of the immune response showed that the antibody titers
gradually increased with the first boost and peaked after the
second boost. The titers started to decrease at day 56, i.e., 1
week after the third boost. The endpoint titer was 256,000.
Comparative ELISA analysis. A comparative evaluation of
the reactivity of the patient sera with the P30 protein and was
carried out with the Serion ELISA Classic kit to determine
whether the P30 protein can be used as an antigen for the devel-
opment of an immunodiagnostic assay for M. pneumoniae infec-
tion. A total of 47 patient serum samples were analyzed for their
reactivities to the rMPN30–pMAL-p2x fusion protein in an
FIG. 2. Amino acid sequence variations among 18 clinical samples. Sam. No., sample number.
FIG. 3. (A) SDS-polyacrylamide gel showing the purification of the P30 protein from E. coli extracts. Lanes: 1, initial flowthrough; 2, wash 1;
3, elution 1; 4, elution 2. (B and C) Western blots of E. coli extracts showing the expression of the P30 protein with antihistidine antibody (B) and
anti-M. pneumoniae antibodies (C). Lanes: 1, prestained protein marker; 2, uninduced P30 protein; 3, induced P30 protein. The numbers on the
left are molecular masses (in kilodaltons).
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ELISA. As shown in Fig. 7, a total of 22 of 28 positive serum
samples (based on the reactivity of the Serion ELISA Classic kit)
were found to be reactive to the P30 protein fusion, while 17 of 19
patient serum samples were found to be negative by our ELISA,
and they also showed no reactivity by use of the commercial kit.
Statistical analysis. A comparative analysis of the P30 pro-
tein ELISA and the assay with the Serion IgM ELISA Classic
kit, which was used as the standard, was done by applying the
diagnostic test. The cutoff value was taken as an absorbance
value of 0.5. At 0.5 absorbance, the cutoff points for the sen-
sitivity and the specificity of P30 protein ELISA were deter-
mined to be 78.57% and 89.47%, respectively.
DISCUSSION
P30, an adhesin protein on the M. pneumoniae surface, lo-
calizes primarily to the terminal organelle. The protein has a
C-terminal proline-rich repeat region that is exposed on the
cell surface. The characterization of HA-negative mutants re-
vealed that P30 is an important adhesin and is also involved in
the gliding motility of the organism (12). In the present study,
we amplified and sequenced the p30 gene of M. pneumoniae
directly from Indian clinical specimens. PCR amplification and
sequence analysis of the p30 gene revealed that there is a
predominance of strain FH-Liu among Indian clinical isolates.
Of the 18 samples studied, the p30 gene sequence from 16
samples showed similarity to the strain FH-Liu p30 gene se-
quence, while the p30 gene sequences amplified from 2 clinical
samples showed similarity with the p30 gene sequence of strain
M-129 (subtype 1). Compared with the sequence of strain
M-129, four base substitutions in the p30 gene that resulted in
three amino acid variations were found in the M. pneumoniae
genomes present in Indian patients. These substitutions were
also present in the p30 gene sequence of the standard FH-Liu
strain of M. pneumoniae. Of these four differences, the last two
nucleotide substitutions that resulted in a single amino acid
change have also been reported in one of the clinical isolates
studied by Dumke et al. (10). To the best of our knowledge,
this is the first report of the p30 gene sequence among Indian
clinical samples. Among these sequences, we did not find any
mutants of the p30 gene with truncated sequences.
Since M. pneumoniae is an organism that is difficult to isolate
and grow, standard methods for the detection of M. pneu-
moniae are serology and PCR. Serological methods are pres-
ently based on the total cell lysate, which sometimes shows
cross-reactivity with other mycoplasmas and microorganisms.
Our group has been interested in developing protocols to pro-
duce large amounts of M. pneumoniae surface antigens. In the
FIG. 5. Immunoblot of the purified P30 fusion protein with indi-
vidual positive and negative patient serum samples and anti-MBP
antibodies. Lanes 7, 10, 24, 40, 73, and 113, individual positive serum
samples; lanes 29 and 101, negative controls (negative individual serum
samples that tested negative with the commercial kit). Lane PM, P30
fusion protein reacted with anti-MBP antibodies.
FIG. 4. (A) Western blot of E. coli extracts showing the expression of the P30 protein with anti-MBP antibody. Lanes: 1, prestained protein
marker; 2, induced P30 protein; 3, uninduced P30 protein. (B) SDS-polyacrylamide gel showing the purification of the P30 fusion protein. Lanes:
1, marker; 2, initial flowthrough; 3, wash 1; 4, wash 2; 5, elution 1; 6, elution 2. (C) Electroelution of the P30 protein from the purified MBP fusion
construct, Lanes: 1, standard protein marker; 2 and 3, eluted P30 fusion protein. (D) Western blot of E. coli extracts showing the expression of
the P30 protein with anti-M. pneumoniae antibodies. Lanes: 1, prestained protein marker; 2 and 3, induced P30 protein. The numbers on the left
are molecular masses (in kilodaltons).
FIG. 6. Immune response in BALB/c mice immunized with the
P30B-MBP fusion protein formulated in CFA or IFA.
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present study, we expressed a fragment of the p30 gene that
includes the complete C-terminal proline-rich amino acid se-
quences. The protein was expressed as a His-tagged and MBP-
P30 fusion protein; however, we failed to obtain the His-tagged
P30 protein in soluble form under nondenaturing conditions.
Nonetheless, we were able to express and purify the MBP-P30
fusion protein in soluble form. The yield of purified protein
was approximately 1 mg/liter. The purified protein was recog-
nized by anti-M. pneumoniae antibodies. Although the P30
protein has previously been expressed in an E. coli expression
vector as well as in Bacillus subtilis, it appears that the protein
was expressed in very small amounts (15, 17).
Previous studies of the P30 protein have mainly been fo-
cused on understanding its role in cytadherence and gliding
motility (9, 11, 16, 19). Its use as an immunodiagnostic mole-
cule has not been explored. As the C-terminal proline-rich
fragment of P30 is exposed on the surface of M. pneumoniae,
we carried out a detailed immunological analysis of the
rMPN30–pMAL-p2x fusion protein. The fusion protein was
immunogenic, as it elicited a boostable immune response in
mice. The protein was recognized by M. pneumoniae-infected
patient sera as well. We next analyzed the reactivity of the
rMPN30–pMAL-p2x fusion protein with patient sera in an
ELISA analysis and compared the reactivity with that obtained
with the Serion ELISA Classic kit. This kit has been reported
to be 100% sensitive and 75% specific, as described in the
manufacturer’s instructions. The sensitivity and the specificity
of our ELISA with the purified MBP-P30B fusion protein were
found to be 78.57% and 89.47%, respectively.
In conclusion, the results from the present study indicate that
the P30 protein is an important antigen and can be used along
with two other adhesin molecules, P1 and P116, for the develop-
ment of a sensitive assay for the diagnosis of M. pneumoniae
infection. The use of this protein to study cytadherence may also
provide insight into the pathophysiology of this disease.
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FIG. 7. Comparative ELISA analysis by the recombinant P30
ELISA and with the Serion Classic IgM ELISA kit with sera from 47
patients. (A) Positive patient sera. (B) Negative patient sera.
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